Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2185–2208 of 4,247 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Study Product Clear all

Conditions: Lupus Nephritis
Interventions: secukinumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 8
States / cities: Birmingham, Alabama • Fontana, California • Los Angeles, California + 5 more

Conditions: Ileus
Interventions: MOA-728, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 374 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 75
States / cities: Benton, Arkansas • Colton, California • Laguna Hills, California + 62 more

Conditions: Acne Vulgaris
Interventions: CLPG Topical Gel 1%, Clindamycin, Placebo; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 1,260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Pain, Thermal Injury, Burns, Hyperalgesia
Interventions: Voriconazole (topical), Topical Sterile Water Placebo Group; Drug
Lead sponsor: Kenneth Hargreaves; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Alzheimer's Disease
Interventions: NGP 555; Drug
Lead sponsor: NeuroGenetic Pharmaceuticals Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Cypress, California

Conditions: Migraine
Interventions: Fremanezumab, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 875 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 178
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 77 more

Conditions: Neovascular Age-Related Macular Degeneration (nAMD)
Interventions: Ranibizumab, ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3, Local Steroid, Topical Steroid, ABBV-RGX-314 Dose 4; Biological · Genetic · Drug
Lead sponsor: AbbVie; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 18
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 15 more

Conditions: Atherosclerotic Cardiovascular Disease
Interventions: Inclisiran; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 30 Years to 50 Years
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 1
States / cities: New York, New York

Conditions: Hilar Cholangiocarcinoma
Interventions: Photodynamic therapy-Photofrin, Stenting procedure, Chemotherapy regimen; Drug · Procedure
Lead sponsor: Concordia Laboratories Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 18
States / cities: Goodyear, Arizona • Scottsdale, Arizona • Los Angeles, California + 14 more

Conditions: Opiate Induced Respiratory Depression
Interventions: CX1739 - 300 mg, CX1739 - 600 mg, CX1739 - 900 mg, Placebo; Drug
Lead sponsor: RespireRx; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Arthritis, Rheumatoid
Interventions: CP-195,543, celecoxib, Methotrexate; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 39
States / cities: Huntsville, Alabama • Scottsdale, Arizona • Upland, California + 35 more

Conditions: Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
Interventions: Galvokimig, Placebo; Biological
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 402 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 16
States / cities: Encino, California • Westminster, California • Miami, Florida + 13 more

Conditions: Alzheimer Disease
Interventions: Salsalate, Placebo; Drug
Lead sponsor: Adam Boxer; Other
Eligibility: 50 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 2
States / cities: San Diego, California • San Francisco, California

Conditions: HIV-1-infection
Interventions: Oral Lenacapavir, F/TAF, Subcutaneous Lenacapavir, TAF, BIC, B/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 49
States / cities: Phoenix, Arizona • Los Angeles, California • Palm Springs, California + 40 more

Conditions: Acne Vulgaris
Interventions: Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2%, CABTREO Topical Gel, Placebo Control; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 382 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Hawthorne, New York

Conditions: Breast Cancer, Breast Neoplasms
Interventions: Taxane, Vinorelbine, Ixabepilone, Eribulin, Chemotherapy; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Covid19
Interventions: Placebo, Fisetin; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Chemotherapy-induced Thrombocytopenia
Interventions: Romiplostim, Placebo; Biological · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 22
States / cities: Jonesboro, Arkansas • Anaheim, California • Orange, California + 18 more

Conditions: Rosacea
Interventions: Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel, Placebo gel; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Stanford, California • Boston, Massachusetts

Conditions: Malaria, Vivax
Interventions: Tafenoquine Control, Tafenoquine dissolution profile X, Tafenoquine SIL; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Scalp Psoriasis
Interventions: UHE-105, Vehicle; Drug
Lead sponsor: Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 2
States / cities: San Diego, California • High Point, North Carolina

Conditions: Breast Cancer
Interventions: HylaCare, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Ulcerative Colitis
Interventions: OPC-6535 Tablets (drug); Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 23
States / cities: Scottsdale, Arizona • Los Angeles, California • Santa Ana, California + 18 more

Conditions: COVID, COVID-19, Corona Virus Infection, Coronavirus Infection, Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere, Coronavirus-19, SARS-CoV 2, SARS Pneumonia
Interventions: hydroxychloroquine, Azithromycin, Ritonavir, Lopinavir; Drug
Lead sponsor: ProgenaBiome; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Ventura, California

Search by objective public record fields.

Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis

A Study Evaluating Intravenous (IV) MOA-728 for the Treatment of Postoperative Ileus (POI) in Participants After Ventral Hernia Repair

Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris

Pilot Study to Compare Topical Voriconazole to Placebo as a Pain Reducing Agent

Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Young Volunteers (Single-ascending Dose)

Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)

The Prevent Coronary Artery Disease Trial

Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)

Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia

A Study Of CP-195543 And Celecoxib Dual Therapy In Subjects With Rheumatoid Arthritis

A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis

Salsalate in Patients Mild to Moderate Alzheimer's Disease

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV

A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.

Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy

COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer

Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea

A Study to Assess the Effects of Dissolution Profile on the Pharmacokinetics of Single Oral Doses of Tafenoquine Tablets and Tafenoquine Stable Isotope Labelled Solution

A Study of the Safety and Efficacy of UHE-105 Shampoo in Subjects With Scalp Psoriasis

HylaCare in the Treatment of Acute Skin Changes in Patients Undergoing Radiotherapy for Breast Cancer

FACTS I: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis

A Study of Combination Therapies to Treat COVID-19 Infection